Competing Endogenous RNA and Coexpression Network Analysis for Identification of Potential Biomarkers and Therapeutics in association with Metastasis Risk and Progression of Prostate Cancer

Table 2

Small molecules that potentially reverse dysregulation of expression profile in lymphatic metastasis and PCa samples, respectively.

CMAP drug name	Enrichment score	Mean score	value
Non-LNM compared with LNM samples
Geldanamycin	-0.983	-0.806	0.001
Econazole	-0.956	-0.804	0.002
6-Bromoindirubin-3-oxime	-0.953	-0.616	0.005
Triamterene	-0.942	-0.449	0.007
Rilmenidine	-0.941	-0.341	0.007
Fludrocortisone	-0.918	-0.388	0.014
Mimosine	-0.909	-0.373	0.017
Tocainide	-0.896	-0.384	0.022
Ethoxyquin	-0.871	-0.330	0.033
Acenocoumarol	-0.812	-0.441	0.049
Normal tissue compared with PCa tissue
Econazole	-0.972	-0.784	0.002
Rilmenidine	-0.968	-0.719	0.002
6-Bromoindirubin-3-oxime	-0.878	-0.529	0.004
Diphenhydramine	-0.957	-0.446	0.004
Naftidrofuryl	-0.955	-0.336	0.004
PF-00539758-00	-0.952	-0.343	0.005
Meteneprost	-0.950	-0.408	0.005
Quipazine	-0.947	-0.397	0.006
Benzamil	-0.841	-0.467	0.008
Azacyclonol	-0.933	-0.368	0.009